Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.36 |
| ▸ | NPY1R | P25929 | 10/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.36 |
| ▸ | NPY2R | P49146 | 6/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587709 | 0.97 | NPY4R (0.36) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL2241867 | 0.90 | NMT1 (0.42) | NPY4RNPY1RNPY5RNPY2RSLC15A2 | |
| SCHEMBL4589289 | 0.87 | NMT1 (0.42) | NPY4RNPY1RNPY5RNPY2RSLC15A2 | |
| SCHEMBL1627262 | 0.86 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL29476474 | 0.85 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL187696 | 0.85 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL2116832 | 0.85 | C3AR1 (0.45) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL4587702 | 0.84 | C3AR1 (0.44) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL2815688 | 0.84 | C3AR1 (0.44) | NPY4RNPY1RNPY5RNPY2RC3AR1 | |
| SCHEMBL5160379 | 0.83 | NPY4R (0.35) | NPY4RNPY1RNPY5RNPY2RC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | PROCYTE CORPORATION (US) | 2010-09-30 | — | — | US | disclosed |
| EP-1613302-B1 | PRESERVED AND STABLE COMPOSITIONS CONTAINING PEPTIDE COPPER COMPLEXES AND METHODS RELATED THERETO | PROCYTE CORP (US) | 2009-12-23 | — | — | EP | disclosed |
| US-7179789-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-09-22 | — | — | US | disclosed |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PROCYTE CORPORATION (US) | 2005-09-08 | — | — | US | disclosed |
| US-6927206-B2 | Compositions and methods for treatment of rosacea | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| US-6927205-B2 | Compositions and methods for treatment of psoriasis | PROCYTE CORPORATION (US) | 2005-08-09 | — | — | US | disclosed |
| EP-0765152-B1 | STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES | PROCYTE CORP (US) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209130-A1 | Compositions and methods for treatment of rosacea | CUTA, AOC1, RCN1 | NPY4R 811/4885NPY1R 171/4885NPY5R 380/4885 |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | NPY4R 1065/4885NPY1R 269/4885NPY5R 596/4885 |
| US-20100249042-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYELASHES AND EYEBROWS | CUTA, TYR, EYA3 | NPY4R 785/4885NPY1R 300/4885NPY5R 402/4885 |
| US-20050197282-A1 | for topical administration of peptide copper complex with corticosteroids, coal tar, anthralin, calcipotriene, and tazarotene; dermatology; cosmetics | PTH1R, TSLP, CYP27B1 | NPY4R 797/4885NPY1R 936/4885NPY5R 1358/4885 |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | NPY4R 496/4885NPY1R 170/4885NPY5R 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.